See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.


Watch a Video on Combination Regimens with POMALYST® (pomalidomide)

Choosing a POMALYST-Containing Regimen

Dr David Siegel summarizes the expansion of POMALYST data across four trials and shares his insights about a POMALYST-containing regimen, including use as early as first relapse, after lenalidomide and a PI.

Watch a Video on POMALYST® (pomalidomide) MOA Play Icon

Mechanism of Action

Explore the mechanism of action of POMALYST.

POMALYST® (pomalidomide) Patient Resources Icon

Resources and tools for healthcare providers

Access HCP Tools

Resources and tools for nurses and their patients

Get Started

Resources and tools for nurses and their patients

Get Started

dex, dexamethasone; DPd, POMALYST + dexamethasone + daratumumab; HCP, healthcare provider; LoT, lines of therapy; MM, multiple myeloma; Pd, POMALYST + dexamethasone; PI, proteasome inhibitor; RRMM, relapsed/refractory multiple myeloma.

References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066. 3. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 4. Daratumumab and hyaluronidase-fihj [package insert]. Horsham, PA: Janssen Biotech, Inc. 5. Bahlis NJ, Siegel D, Schiller G, et al. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leuk Lymphoma. 2022 Feb 8;1-11. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed December 8, 2022. To view the most recent and complete version of the guidelines, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 7. Bristol-Myers Squibb Co; January 2023.